To investigate whether the low expression of INMT is unique to prostate cancer or the universality of cancer, we have used pan-cancer exploration of the Tumor Immune Estimation Resource (TIMER) data resource to show that the RNA expression of INMT was lower in most cancer tissues, such as bladder urothelial carcinoma, breast invasive carcinoma, ceramic square cell carcinoma and endocervical adenocarcinoma, colon adenocarcinoma, and head and neck squamous cell carcinoma, and kidney chromophobe (Figure 1H). This evidence concerns the gene INMT and bladder transitional cell carcinoma.